MCCULLOCH KEVIN (See Remarks) received a stock award from XERIS BIOPHARMA HOLDINGS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 8/2/2024ACC: 0001867096-24-000144
Officer· See Remarks
Since Mar 2026
+350K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
350K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+150K
Price / share
—
Trade value
—
% of position
10.3%
8/1/2024
1.45M→1.60M
Total
Net shares
+150K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/1/2024 | A · Award | +150K | — | — | 10.3% | 1.45M | 1.60M |
| Total | +150K | $0.00 | ||||||
Derivative Transactions1
Stock Appreciation Right
Direct
Converts to
Common Stock
200K shares
Shares
+200K
Strike price
2.43
Held after
200K
Exercisable
—
8/1/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Appreciation Right Direct | Common Stock200K shares | 8/1/2024 | A · Award | +200K | 2.43 | — | 200K |